New Enterprise Associates

Regression Games focuses on enhancing competitive gaming through artificial intelligence. The company develops tools aimed at simplifying the game development process, offering a platform that automates quality assurance and game balancing. By utilizing AI agents, Regression Games ensures that automation is efficient and effective, allowing game developers to streamline their workflows. This approach not only supports studios in improving their games but also makes AI-driven gaming experiences more accessible and enjoyable for players.

ForAllSecure Inc. is a cybersecurity company focused on enhancing software security through advanced testing solutions. Established in 2012 and headquartered in Pittsburgh, Pennsylvania, with additional locations in Palo Alto, California, and Crystal City, Virginia, the company leverages patented technology developed from research at Carnegie Mellon University. Its primary product, Mayhem, is a fuzz testing solution that automates the detection of software defects at scale and integrates seamlessly into continuous integration pipelines, thereby streamlining security processes for organizations. ForAllSecure partners with Fortune 1000 companies across industries such as aerospace, automotive, and high-tech to provide scalable security testing that keeps pace with rapid development cycles. The company has received recognition for its innovative contributions to cybersecurity, including winning DARPA's Cyber Grand Challenge and being listed among the 50 Smartest Companies by MIT Technology Review.

Belong Health is a health insurance company focused on delivering Medicare Advantage and special needs plan products. The company collaborates with local health plans to provide regionally informed and compassionate care to a growing community. By partnering with these regional health plans, Belong Health aims to create a straightforward Medicare experience for eligible members, facilitating access to quality healthcare through trusted insurance partners. This approach allows Belong Health to launch or enhance market-leading plans that address the specific needs of its members.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The Company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Vesper Medical, Inc. is a medical device company established in 2016 and based in Wayne, Pennsylvania. The company focuses on developing minimally invasive peripheral vascular products specifically designed for treating deep venous disease. Its flagship offering, the Vesper DUO Venous Stent System, features a unique combination of strength and flexibility that addresses the complex anatomical challenges of venous stenting, particularly in the iliac and femoral veins. Vesper Medical aims to provide safe, effective, and user-friendly solutions for both patients and healthcare providers, enhancing the treatment of deep venous conditions.

Lungpacer Medical Inc. is a medical device company based in Vancouver, Canada, with an additional office in Exton, Pennsylvania. Founded in 2009, the company specializes in developing therapeutic solutions for critically ill patients who require mechanical ventilation. Its primary product, the Lungpacer DPT System, is a diaphragm pacing system designed to preserve and restore the strength of the diaphragm muscle. This innovative system utilizes the body's nervous system to stimulate the diaphragm, enabling repetitive exercises that help rebuild muscle strength and endurance. By addressing diaphragm muscle disuse atrophy, Lungpacer aims to improve the overall respiratory health of patients, facilitating better outcomes in critical care settings.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

Nth Round allows founders, shareholders, and investors of private companies to trade their equity anytime, anywhere.

Vesper Medical, Inc. is a medical device company established in 2016 and based in Wayne, Pennsylvania. The company focuses on developing minimally invasive peripheral vascular products specifically designed for treating deep venous disease. Its flagship offering, the Vesper DUO Venous Stent System, features a unique combination of strength and flexibility that addresses the complex anatomical challenges of venous stenting, particularly in the iliac and femoral veins. Vesper Medical aims to provide safe, effective, and user-friendly solutions for both patients and healthcare providers, enhancing the treatment of deep venous conditions.

Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing innovative treatments for severe diseases involving fibrosis and inflammation. Founded in 2008, Complexa specializes in the research and development of endogenous human cell signaling technologies, particularly through the synthesis of endogenous nitro-fatty acids. Their lead compound, CXA-10, is an oral nitrated fatty acid being developed for the treatment of focal segmental glomerulosclerosis and pulmonary arterial hypertension. The company aims to enhance existing anti-inflammatory and metabolic signaling pathways to promote recovery from acute and chronic tissue injuries and diseases, targeting a range of inflammatory, fibrotic, and central nervous system disorders.

Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.

Curalate, Inc. operates an online platform designed to facilitate product discovery and enhance the shopping experience for consumers. By transforming images and videos into digital storefronts, the platform allows brands to integrate their products into social media channels, advertisements, and emails effectively. Curalate provides tools for brands to automatically share content, track social media engagement metrics, and monitor campaigns, competitors, and influencers. Established in 2011 and originally named Storably, Curalate is headquartered in Philadelphia, Pennsylvania, with additional offices in New York, Seattle, and London. The company serves numerous prominent brands, including Gap, Neiman Marcus, and Sephora, by enabling a seamless transition from product discovery on social media to on-site purchases. As of July 2020, Curalate operates as a subsidiary of Bazaarvoice, Inc.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.

Duolingo, Inc. develops a language learning platform for classrooms. It offers English fluency tests for businesses, schools, and governments globally. Duolingo, Inc. was founded in 2011 and is based in Pittsburgh, Pennsylvania.

Intact Vascular, Inc., a medical device company, develops medical devices for minimally invasive peripheral vascular procedures. The company offers Tack Endovascular System, a device that offers optimization of peripheral balloon angioplasty results during the treatment of peripheral arterial disease (PAD) and critical limb ischemia (CLI). Intact Vascular, Inc. was formerly known as Tackit Vascular LLC. The company was founded in 2011 and is based in Wayne, Pennsylvania.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

Uber Technologies, Inc. is a technology company that operates a mobile application connecting consumers with independent drivers for ridesharing services, as well as facilitating food delivery through its Eats segment. Founded in 2009 and headquartered in San Francisco, Uber has expanded its operations to over 600 cities worldwide, serving customers across North America, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. The company has diversified its offerings into five segments: Rides, Eats, Freight, Other Bets, and Advanced Technologies Group. The Rides segment enables users to request rides from a variety of vehicle types, while the Eats segment allows for restaurant discovery and food delivery. The Freight segment connects carriers with shippers for logistics services. Uber is also focused on developing autonomous vehicle technology through its Advanced Technologies Group. By leveraging its platform, Uber aims to enhance urban mobility and deliver innovative transportation solutions globally.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.

Curalate, Inc. operates an online platform designed to facilitate product discovery and enhance the shopping experience for consumers. By transforming images and videos into digital storefronts, the platform allows brands to integrate their products into social media channels, advertisements, and emails effectively. Curalate provides tools for brands to automatically share content, track social media engagement metrics, and monitor campaigns, competitors, and influencers. Established in 2011 and originally named Storably, Curalate is headquartered in Philadelphia, Pennsylvania, with additional offices in New York, Seattle, and London. The company serves numerous prominent brands, including Gap, Neiman Marcus, and Sephora, by enabling a seamless transition from product discovery on social media to on-site purchases. As of July 2020, Curalate operates as a subsidiary of Bazaarvoice, Inc.

Duolingo, Inc. develops a language learning platform for classrooms. It offers English fluency tests for businesses, schools, and governments globally. Duolingo, Inc. was founded in 2011 and is based in Pittsburgh, Pennsylvania.

Scratch Music Group, Inc. operates as a music and technology company. The company operates DJ and music production learning centers in New York, Miami, Los Angeles, Atlanta, Chicago, Philadelphia, as well as through satellite locations at hotels, resorts, and on cruise ships worldwide. It also creates events for brands worldwide; and provides wedding DJ services. The company was founded in 2002 and is based in New York, New York.

Scratch Music Group, Inc. operates as a music and technology company. The company operates DJ and music production learning centers in New York, Miami, Los Angeles, Atlanta, Chicago, Philadelphia, as well as through satellite locations at hotels, resorts, and on cruise ships worldwide. It also creates events for brands worldwide; and provides wedding DJ services. The company was founded in 2002 and is based in New York, New York.

Curalate, Inc. operates an online platform designed to facilitate product discovery and enhance the shopping experience for consumers. By transforming images and videos into digital storefronts, the platform allows brands to integrate their products into social media channels, advertisements, and emails effectively. Curalate provides tools for brands to automatically share content, track social media engagement metrics, and monitor campaigns, competitors, and influencers. Established in 2011 and originally named Storably, Curalate is headquartered in Philadelphia, Pennsylvania, with additional offices in New York, Seattle, and London. The company serves numerous prominent brands, including Gap, Neiman Marcus, and Sephora, by enabling a seamless transition from product discovery on social media to on-site purchases. As of July 2020, Curalate operates as a subsidiary of Bazaarvoice, Inc.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule mimetic of superoxide dismutase designed to address radiation-induced severe oral mucositis in patients with head and neck cancer. It is currently undergoing Phase III clinical trials for this indication and Phase IIa trials for treating radiotherapy-induced esophagitis in lung cancer patients. Additionally, Galera is developing a second candidate, GC4711, which is in Phase I/II trials for pancreatic and lung cancers. Founded in 2012 and headquartered in Malvern, Pennsylvania, Galera Therapeutics is dedicated to transforming cancer treatment through advancements in oxygen metabolic pathways.

Bravo Health, Inc. provides managed care services. It offers Medicare advantage options to allow members to choose the right plan for them; and special needs plans for those who are receiving institutional care, who have chronic health conditions, or who are eligible for both Medicare and Medicaid benefits. The company also provides private fee-for-service plans, which provide members the freedom to determine from whom they receive their health care; and part D prescription plans for those who only need coverage for their medications. It offers its plans to members in Delaware, Maryland, Pennsylvania, Texas, Washington, D.C., California, Florida, Illinois, Michigan, New Jersey, New York, Ohio, and West Virginia. Bravo Health, Inc. was formerly known as Elder Health, Inc. The company was founded in 1996 and is based in Baltimore, Maryland.

Duolingo, Inc. develops a language learning platform for classrooms. It offers English fluency tests for businesses, schools, and governments globally. Duolingo, Inc. was founded in 2011 and is based in Pittsburgh, Pennsylvania.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

Curalate, Inc. operates an online platform designed to facilitate product discovery and enhance the shopping experience for consumers. By transforming images and videos into digital storefronts, the platform allows brands to integrate their products into social media channels, advertisements, and emails effectively. Curalate provides tools for brands to automatically share content, track social media engagement metrics, and monitor campaigns, competitors, and influencers. Established in 2011 and originally named Storably, Curalate is headquartered in Philadelphia, Pennsylvania, with additional offices in New York, Seattle, and London. The company serves numerous prominent brands, including Gap, Neiman Marcus, and Sephora, by enabling a seamless transition from product discovery on social media to on-site purchases. As of July 2020, Curalate operates as a subsidiary of Bazaarvoice, Inc.

Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.

Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.

Vitae Pharmaceuticals is a clinical-stage biotechnology company dedicated to discovering and developing innovative small molecule drugs aimed at addressing significant unmet medical needs. The company is focused on a range of diseases, including autoimmune disorders such as psoriasis and multiple sclerosis, atopic dermatitis, type 2 diabetes, acute coronary syndrome, and Alzheimer's disease. Vitae's product pipeline features VTP-43742, currently in Phase I clinical trials for autoimmune disorders, VTP-38543 in Phase IIa for atopic dermatitis, and VTP-34072 in Phase II clinical trials for type 2 diabetes. Additionally, the company is advancing BI 1147560 for Alzheimer's disease and VTP-38443 for acute coronary syndrome. Founded in 2001 and headquartered in Fort Washington, Pennsylvania, Vitae Pharmaceuticals operates as a subsidiary of Allergan plc.

Rinera Networks is a professional in internet video distribution. It is based in Pittsburgh, Pennsylvania.

Vitae Pharmaceuticals is a clinical-stage biotechnology company dedicated to discovering and developing innovative small molecule drugs aimed at addressing significant unmet medical needs. The company is focused on a range of diseases, including autoimmune disorders such as psoriasis and multiple sclerosis, atopic dermatitis, type 2 diabetes, acute coronary syndrome, and Alzheimer's disease. Vitae's product pipeline features VTP-43742, currently in Phase I clinical trials for autoimmune disorders, VTP-38543 in Phase IIa for atopic dermatitis, and VTP-34072 in Phase II clinical trials for type 2 diabetes. Additionally, the company is advancing BI 1147560 for Alzheimer's disease and VTP-38443 for acute coronary syndrome. Founded in 2001 and headquartered in Fort Washington, Pennsylvania, Vitae Pharmaceuticals operates as a subsidiary of Allergan plc.

TargetRx provides pharmaceutical and biotech companies with unique insight into the true drivers of product choice and adoption for their brands, so that they can confidently take the actions that will grow their businesses and help patients. They offer a suite of solutions that extends from the pipeline through patent expiry.

Nucleonics is a biotechnology company focused on RNA interference-based therapeutics.

Vitae Pharmaceuticals is a clinical-stage biotechnology company dedicated to discovering and developing innovative small molecule drugs aimed at addressing significant unmet medical needs. The company is focused on a range of diseases, including autoimmune disorders such as psoriasis and multiple sclerosis, atopic dermatitis, type 2 diabetes, acute coronary syndrome, and Alzheimer's disease. Vitae's product pipeline features VTP-43742, currently in Phase I clinical trials for autoimmune disorders, VTP-38543 in Phase IIa for atopic dermatitis, and VTP-34072 in Phase II clinical trials for type 2 diabetes. Additionally, the company is advancing BI 1147560 for Alzheimer's disease and VTP-38443 for acute coronary syndrome. Founded in 2001 and headquartered in Fort Washington, Pennsylvania, Vitae Pharmaceuticals operates as a subsidiary of Allergan plc.

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

Laurel Networks is focused on the development of IP service edge routers and management solutions. Laurel Networks was founded in 1999 and is based in Pittsburgh, Pennsylvania.

TargetRx provides pharmaceutical and biotech companies with unique insight into the true drivers of product choice and adoption for their brands, so that they can confidently take the actions that will grow their businesses and help patients. They offer a suite of solutions that extends from the pipeline through patent expiry.

As of January 30, 2009, Novacea, Inc. was acquired by Transcept Pharmaceuticals, Inc., in a reverse merger transaction. Novacea, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing therapies for the treatment of cancer. The company’s product candidates include Asentar, which is in Phase III clinical trial for the treatment of androgen-independent prostate cancer and in Phase II clinical trial for the treatment of advanced pancreatic cancer; and AQ4N, a hypoxia-activated prodrug in Phase Ib/IIa clinical trial for the treatment of glioblastoma multiforme. It has license and collaboration agreements with Aventis Pharmaceuticals, Inc.; Oregon Health & Science University; University of Pittsburgh; KuDOS Pharmaceuticals Limited; and BTG International Limited. The company was founded in 2001 and is headquartered in South San Francisco, California.

TargetRx provides pharmaceutical and biotech companies with unique insight into the true drivers of product choice and adoption for their brands, so that they can confidently take the actions that will grow their businesses and help patients. They offer a suite of solutions that extends from the pipeline through patent expiry.

TargetRx provides pharmaceutical and biotech companies with unique insight into the true drivers of product choice and adoption for their brands, so that they can confidently take the actions that will grow their businesses and help patients. They offer a suite of solutions that extends from the pipeline through patent expiry.

Laurel Networks is focused on the development of IP service edge routers and management solutions. Laurel Networks was founded in 1999 and is based in Pittsburgh, Pennsylvania.

PPONEXT is a PPO services company that provides healthcare management and network services. PPONEXT offers access to a network of medical care providers, hospitals, and ancillary facilities to group health, workers' compensation, and other insurance payers in the Midwest, Texas, California, Florida, New Jersey, and Pennsylvania.

InSoft is a provider of collaborative computing, desktop conferencing, and distributed digital video development tools and applications. The company has been called a pioneer in the desktop videoconferencing market and is credited with developing Internet media streaming and VoIP/collaborative software applications that would later be developed into NetscapeConference and NetscapeMedia Server.